Enhanced magnetic resonance contrast of iron oxide nanoparticles embedded in a porous silicon nanoparticle host

Abstract

In this report, we prepared a porous Si nanoparticle with a pore morphology that facilitates the proximal loading and alignment of magnetite nanoparticles. We characterized the composite materials using superconducting quantum interference device magnetometry, dynamic light scattering, transmission electron microscopy, and MRI. The in vitro cytotoxicity of the composite materials was tested using cell viability assays on human liver cancer cells and rat hepatocytes. An in vivo analysis using a hepatocellular carcinoma (HCC) Sprague Dawley rat model was used to determine the biodistribution properties of the material, while naïve Sprague Dawley rats were used to determine the pharmocokinetic properties of the nanomaterials. The composite material reported here demonstrates an injectable nanomaterial that exploits the dipolar coupling of superparamagnetic nanoparticles trapped within a secondary inorganic matrix to yield significantly enhanced MRI contrast. This preparation successfully avoids agglomeration issues that plague larger ferromagnetic systems. A Fe 3 O 4 :pSi composite formulation consisting of 25% by mass Fe 3 O 4 yields an maximal T2* value of 556 mM Fe −1 s −1 . No cellular (HepG2 or rat hepatocyte cells) or in vivo (rat) toxicity was observed with the formulation, which degrades and is eliminated after 4-8 h in vivo. The ability to tailor the magnetic properties of such materials may be useful for in vivo imaging, magnetic hyperthermia, or drug-delivery applications.

Recent Advances in Porous silicon-based Therapeutic Delivery

“…With the incorporation of superparamagnetic iron oxide nanoparticles, direct imaging of the PSi particles in vivo using MRI is possible. To-date, two methods for incorporating iron oxide into the PSi nanostructure have been investigated; direct deposition of preformed iron oxide nanoparticles [11,12] and the precipitation of iron oxide nanocrystals [13]. For example, Gizzatov et al successfully demonstrated enhanced tumor accumulation of iron oxide-PSi composites, enabling much smaller iron doses (0.5 mg Fe kg -1 animal) than currently used [12].…”